Latest research on Pemetrexed

Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.

Pemetrexed indications

Pemetrexed is more effective than Docetaxel or Gemcitabine as a treatment for patients with non-squamous NSCLC, with an overall favorable toxicity profile [20,21]. [source, 2016]
However, Pemetrexed is considered more effective than Gefitinib for the second-line treatment in patients with EGFR wild-type disease. [source, 2016]
Docetaxel is considered more effective than Pemetrexed and Erlotinib for the second-line treatment of advanced or metastatic squamous NSCLC. [source, 2016]
For example, in using improvement in 2-year overall survival as the heath outcome effect, the ICER is ~$3,800 for bevacizumab for the treatment of NSCLC (99), ~$4,800 for Pemetrexed for the treatment of NSCLC (100), ~$3,700 for Imatinib for the treatment of chronic myeloid leukemia (101), compared to a significantly reduced cost for carbon-ion therapy for recurrent colorectal adenocarcinoma (102). [source, 2016]
For example, the antifolate methotrexate dramatically sensitizes cells to the activating effects of AICAR55, while Pemetrexed can activate AMPK even in the absence of exogenous AICAR56. [source, 2016]
The patients were excluded for any contraindications for Pemetrexed or bevacizumab or for general radiotherapy within 2 weeks, stereotactic brain radiotherapy within 7 days, major surgery within 28 days, minor surgery within 7 days, neurosurgical resection or brain biopsy within 3 months before day 1, cycle 1. [source, 2015]
Pemetrexed is a multi-targeted inhibitor of the Folate metabolic pathway, and its effectiveness in NSCLC compared with Docetaxel has been demonstrated in several clinical trials. [source, 2015]
In order to obtain a more detailed risk–benefit analysis of Docetaxel, several clinical trials have investigated the effectiveness and safety between Docetaxel and Pemetrexed or Docetaxel and vinca alkaloid. [source, 2015]
Since Docetaxel had not previously been comprehensively compared with these drugs, we conducted the systematic review and meta-analysis for all the eligible high-quality Phase III randomized controlled trials to compare the effectiveness and safety between Docetaxel and Pemetrexed or Docetaxel and vinca alkaloid. [source, 2015]
Present treatment methods include: antifolate chemotherapy drug Pemetrexed, which is only effective for treating lung adenocarcinoma (ADC);1 Bevacizumab, which should be avoided in lung squamous cell carcinoma (SQCC);1 epidermal growth factor receptor–tyrosine-kinase inhibitor (EGFR–TKI) therapy, which is only effective in treating lung ADC with EGFR gene mutations;2 and Crizotinib, which is only effective in treating patients with anaplastic lymphoma kinase (ALK) gene rearrangement. [source, 2015]